Monthly Archives: July 2015

IAS 2015: As HPTN 052 ends, Dr. Cohen confirms findings with new insights

By on .

Those whose antiretroviral treatment was delayed never recovered the immune cell counts achieved by those who initiated treatment earlier VANCOUVER, Canada – The first findings from the original “game-changing” HIV treatment study that Science magazine hailed as its “Breakthrough of the Year,” came four years ago, after trial monitors determined they were too good to keep under […]

IAS 2015: While “game-changing,” START trial draws “line in the sand” and sets “time a’ ticking” to stop preventable illnesses and death, calls for action are accompanied by questions of impact of inequities, obstacles

By on .

Study also showed that most commonly used measure — CD4 count does not give accurate projection of illness risk VANCOUVER, Canada – Mostly, the findings of the START trial, detailed in a session here today give rise to words of unbridled vindication and ambition. With that they have also brought a challenge. Showing more than double […]

IAS 2015: Tuberculosis and poor implementation of proven interventions threaten people with HIV and TB

By on .

VANCOUVER, Canada – Isoniazid preventive therapy is as effective in staving off tuberculosis as preemptively treating patients with HIV for tuberculosis, research results released here this morning showed. The findings came in one of a series of presentations this morning highlighting challenges posed by tuberculosis to the lives and well-being of people living with HIV, and failures to use proven […]

IAS 2015: WHO testing guidelines tackle “the most problematic” 90 of 90-90-90 with look at strategies

By on .

WHO releases 2015 Consolidated Guidelines on HIV Testing Services with 5 Cs: Consent Confidentiality, Counselling, Correct Results and Connection VANCOUVER, Canada – It is lost on no one here that history in the fight against AIDS was made in this city once before, nearly two decades ago with the announcement that a combination of three […]

IAS 2015: Researchers, clinicians, leaders sign Vancouver Consensus

By on .

VANCOUVER, Canada – A call for all countries to change policies, move resources, and lead efforts to provide antiretroviral drugs to treat all people living with HIV and to prevent transmission of the virus including through prophylactic use has been signed by heads of the worlds largest donor AIDS programs, the leader of UNAIDS, and […]

IAS 2015: WHO offers “sneak peek” at treatment guidelines, including treatment for all

By on .

VANCOUVER, Canada – Treatment eligibility for everyone diagnosed with HIV without a wait for the virus to damage their immune systems, the option of treatment initiation for all pregnant women with HIV, integration of new options for first line treatment were among changes that will be spelled out in the next World Health Organization guidelines for HIV treatment […]

Live from Vancouver: Breaking news and in-depth coverage of IAS 2015

By on .

When the International AIDS Society 2015 Conference on HIV Pathogenesis, Treatment & Prevention  convenes in Vancouver, British Columbia Sunday, Science Speaks will be there, bringing live coverage of breaking news and reporting on presentations from leading clinicians and researchers. Stay tuned July 19 – 22 for updates on the START trial, HPTN 052, optimizing treatment, […]

With UNAIDS as common denominator, reports bring impetus, optimism, and now, realities

By on .

Kaiser/UNAIDS report looks at donor funding for HIV responses and sees sole donor preventing drop in dollars First came the UNAIDS Lancet report, which warned that without accelerated movement to greatly increase access to antiretroviral treatment for people living with HIV worldwide, progress against the epidemic would not only stall, but reverse. Next came the […]

People with HIV who inject drugs benefit most from integrated treatment, study finds

By on .

While antiretroviral treatment and opioid substitution therapy (methadone, for example) each increase survival rates among people who inject drugs and live with HIV, the two treatments lower risks of dying from all causes, including those stemming from drug use and HIV, most effectively when both are available at the same time, a study reported in […]